Ocwen Financial Corporation (OCN), Charles River Laboratories International, Inc. (CRL)


(NYSE:CRL) released that it has inked into a definitive agreement to acquire MPI Research for approximately $800 million in cash, subject to customary closing adjustments. Riverhead Capital Management LLC raised its stake in Charles River Laboratories Intl.by 14.7% in the second quarter. YorkBridge Wealth Partners LLC lifted its position in Charles River Laboratories Intl.by 445.5% during the 3rd quarter. State Street Corp now owns 1,268,308 shares of the medical research company's stock valued at $128,288,000 after buying an additional 28,365 shares during the last quarter. JOHST DAVID P also sold $2.72 million worth of Charles River Laboratories International, Inc. With the fourth quarter's $478.5 million revenue from continuing operations, the CRO reported a revenue increase by 10.5% to $1.86 billion in 2017, whereas organic revenue growth was 6.7%. Advisor Group Inc. now owns 1,538 shares of the medical research company's stock valued at $165,000 after buying an additional 945 shares in the last quarter. Finally, Zions Bancorporation acquired a new stake in Charles River Laboratories Intl.in the third quarter valued at $212,000.

Founded in 1947, Charles River is more than twice as old as the biotech industry it serves. (NYSE:CRL) with a price target of $108.00.

He also said, "MPI's 1-million-square-foot, single-site facility in MI will provide needed capacity to meet current and future demand". Employees Retirement System Of Ohio stated it has 0.02% in Charles River Laboratories International, Inc. Charles River Laboratories has $124 highest and $65 lowest target.

Expert analysts at the SunTrust Robinson Humphrey research division increased shares of Charles River (NYSE:CRL) from a Hold to a Buy on Wednesday, 14 February.

Ocwen Financial Corporation (NYSE:OCN) shares were trading higher by 5.62 percent ($0.19) at $3.57 a piece in Tuesday's session. This allows me to assess different companies on a similar basis, using new information.

They expect $1.26 EPS, up 3.97% or $0.05 from last year's $1.21 per share.

More news: ICE lawyer due in court on charges he stole immigrants' IDs

On 1/2/2018 David Ross Smith, Insider, sold 5,486 with an average share price of $109.53 per share and the total transaction amounting to $600,881.58. Amp Investors Ltd holds 8,667 shares. As per Tuesday, April 26, the company rating was initiated by Gabelli.

A number of other large investors also recently added to or reduced their stakes in CRL. The stock was sold at an average price of $102.40, for a total transaction of $1,047,244.80. The disclosure for this sale can be found here. Insiders have sold a total of 195,673 shares of company stock worth $2,644,046 in the last three months. (CRL) most recent 13F filing, the company has 47 new institutional holders - accounting for 877,745 shares of its common stock. The stock has a consensus rating of "Buy" and an average price target of $114.85. Credit Suisse Group reiterated a "hold" rating and set a $108.00 target price on shares of Charles River Laboratories Intl.in a research report on Thursday. As per Wednesday, June 21, the company rating was upgraded by Wells Fargo. Robert W. Baird set a $117.00 price target on Charles River Laboratories Intl. and gave the company a "buy" rating in a research note on Monday, November 13th. For Charles River Laboratories International, its most recent earnings (trailing twelve month) is US$198.05M, which compared to the prior year's level, has moved up by 38.23%. (NASDAQ:CRL), 6 rate it "Buy", 2 "Outperform", 10 "Underperform", 0 "Sell", while 0 "Hold". The rating was upgraded by Jefferies to "Buy" on Monday, October 9.

COPYRIGHT VIOLATION NOTICE: This story was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of global trademark & copyright laws.

"In addition to meeting our disciplined acquisition criteria, MPI is an exceptional strategic fit for Charles River, because it incorporates the key attributes we require in an acquisition: access to growing end markets, high-quality services, scientific expertise and complementary capabilities", said James Foster, chairman and CEO, Charles River Laboratories.

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.